CagriSema combines semaglutide, the active ingredient in Wegovy, with a molecule that mimics a pancreatic hormone.

WVU Medicine is playing a lead role in a national clinical study of a minimally invasive surgical procedure for people who've ...

In the Phase IIIb STEP UP trial, 7.2mg Wegovy demonstrated statistically significant ... In May 2023, the company reported positive outcomes from its OASIS 1 Phase IIIa trial of oral semaglutide ...

Ozempic and Wegovy maker Novo Nordisk quieted Wall Street's concerns with its fourth-quarter results and 2025 outlook.

People who stayed on a 7.2 milligram weekly dose of semaglutide lost around 20% of their body weight over 72 weeks.

With GLP-1-related drugs having won the race to weight loss approval, attention at many obesity-focused biopharmas has turned ...

People who have struggled with their weight have found relief with a new drug. But then their weight loss ground to a halt. A ...

After 12 weeks, weight loss with the drug was 13% of body weight, compared to 1% with placebo, which the company said was around twice the level achieved with Wegovy ... in the STEP 9 trial.

Novo Nordisk said that patients taking a higher dose of its blockbuster Wegovy obesity shot lost ... least 25% of their weight in the trial that was dubbed Step Up, it said. Sydbank senior analyst ...

Obesity drug maker Novo Nordisk forecast slower growth this year after Wegovy sales more than doubled in the fourth quarter, ...

The company added that, as expected from the GLP-1 class ... with Wegovy,” said Martin Holst Lange, NVO’s executive vice president for drug development. The company’s second trial, STEP ...